LY-333,531 hydrochloride

• CAT Number: I002216
• CAS Number: 169939-93-9
• Molecular Formula: C₂₈H₂₉ClN₄O₃
• Molecular Weight: 505.01
• Purity: ≥95%
• Target: PKC
• Solubility: DMSO: ≤ 6.8 mg/mL (Need ultrasonic and warming)
• Storage: Store at -20C
• InChI: InChI=1S/C28H28N4O3.ClH/c1-30(2)15-18-11-12-31-16-21(19-7-3-5-9-23(19)31)25-26(28(34)29-27(25)33)22-17-32(13-14-35-18)24-10-6-4-8-20(22)24;/h3-10,16-18H,11-15H2,1-2H3,(H,29,33,34);1H/t18-;/m0./s1
• InChIKey: NYQIEYDJYFVLPO-FERBBOLQSA-N
• SMILES: CN(C)CC1CCN2C=C(C3=CC=CC=C32)C4=C(C5=CN(CCO1)C6=CC=CC=C65)C(=O)NC4=O.Cl

LY-333,531 hydrochloride (Cat.No:I002216) is a selective inhibitor of protein kinase C-beta (PKC-β). It exhibits anti-inflammatory and anti-diabetic properties by blocking PKC-β-mediated signaling pathways. This compound has shown potential in the treatment of diabetic complications and inflammation-related disorders. Further research is being conducted to explore its therapeutic applications and safety profile.

Reference

[1]. Jirousek MR et al. (S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H)-d ione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase C beta. J Med Chem. 1996 Jul 5;39(14):2664-71.
[2]. Al-Onazi AS et al. Ruboxistaurin attenuates diabetic nephropathy via modulation of TGF-β1/Smad and GRAP pathways. J Pharm Pharmacol. 2016 Feb;68(2):219-32.